Characteristics | N (%) |
---|---|
Total advanced incident cancer cases from January 1, 2010 to January 31, 2018 (N, %)a,b | |
Advanced stage at diagnosis, N (%)c | 12,237 (96.67%) |
Diagnosed as early stage and progressed to advanced stage, N (%) | 422 (3.33%) |
Age (years) | |
Mean (SD) | 61.94 (14) |
Q1 | 53 |
Median | 62 |
Q3 | 72 |
Region | |
Midwest | 3436 (28.48%) |
Northeast | 2293 (19.01%) |
South | 2976 (24.67%) |
West | 3358 (27.84%) |
Year of index date | |
2010-2011 | 4712 (37.22%) |
2012-2014 | 4468 (35.30%) |
2015-2018 | 3479 (27.48%) |
Plan type | |
Commercial | 9288 (73.37%) |
Medicare Advantage | 1511 (11.94%) |
Medicare, Other | 1860 (14.69%) |
Duration of health plan membership prior to advanced stage index date (months) | |
Mean (SD) | 48.16 (28.25) |
Q1 | 23.24 |
Median | 48.20 |
Q3 | 68.86 |
Duration of follow-up (months) | |
Mean (SD) | 24.52 (23.28) |
Q1 | 6.47 |
Median | 17.25 |
Q3 | 35.19 |
Deyo-Charlson Comorbidity Index (DCI) during follow-up | |
Mean (SD) | 6.34 (2.63) |
Q1 | 5 |
Median | 6 |
Q3 | 8 |
Number of drugs dispensed during follow-up | |
Mean (SD) | 12.61 (9.76) |
Q1 | 5 |
Median | 11 |
Q3 | 18 |